Cite
HARVARD Citation
Mayer-Hamblett, N. et al. (2023). Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet. 11 (4), pp. 329-340. [Online].